Abstract:Receptor interacting serine/threonine protein kinase 1 (RIPK1) activation and necroptosis have been genetically and mechanistically linked with human multiple sclerosis and neurodegenerative diseases for which demyelination is a common key pathology. Demyelination can be healed through remyelination which is mediated by new oligodendrocytes derived from the adult oligodendrocyte progenitor cells (OPCs). Unfortunately, the efficiency of remyelination declines with progressive aging partially due to the depletion of OPCs following chronic or repeated demyelination. However, to our knowledge, so far there is no drug which enhances proliferation of OPCs, and it is unknown whether inhibiting RIPK1 activity directly affect OPCs, the central player of remyelination. Using TNFα induced RIPK1-dependent necroptosis in Jurkat FADD −/− cells as a cell death assay, we screened from 2112 FDA-approved drugs and the drug candidates of new RIPK1 inhibitors selected by ourselves, and identified ZJU-37, a small molecule modified by introducing an amide bond to Nec-1s, is a new RIPK1 kinase inhibitor with higher potency than Nec-1s which has the best reported potency. We unveil in addition to protecting myelin from demyelination and axons from degeneration, ZJU-37 exhibits a new role on promoting proliferation of OPCs and enhancing remyelination by inhibiting RIPK1 kinase activity with higher potency than Nec-1s. Mechanistically, ZJU-37 promotes proliferation of OPCs by enhancing the transcription of platelet derived growth factor receptor alpha via NF-κB pathway. This work identifies ZJU-37 as a new drug candidate which enhances remyelination by promoting proliferation of OPCs, paving the way for a potential drug to enhance myelin repair.

Investigation on the Chemical Space of the Substituted Triazole Thio-Benzoxazepinone RIPK1 Inhibitors

Profiling of the chemical space on the phenyl group of substituted benzothiazole RIPK3 inhibitors

Structure-based Bioisosterism Design of Thio-Benzoxazepinones As Novel Necroptosis Inhibitors.

Insight from Linker Investigations: Discovery of a Novel Phenylbenzothiazole Necroptosis Inhibitor Targeting Receptor-Interacting Protein Kinase 1 (RIPK1) from a Phenoxybenzothiazole Compound with Dual RIPK1/3 Targeting Activity

Structure-Based Design of Novel Alkynyl Thio-Benzoxazepinone Receptor-Interacting Protein Kinase-1 Inhibitors: Extending the Chemical Space from the Allosteric to ATP Binding Pockets.

Analysis on Benzothiazole Necroptosis Inhibitors with Chiral Substitutions in the Solvent-Accessible Region of RIP Kinase Domain

Discovery, Optimization and Evaluation of Isothiazolo[5,4-B]pyridine Derivatives As RIPK1 Inhibitors with Potent in Vivo Anti-Sirs Activity

N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[ d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure-Activity Relationships, and in Vivo Efficacy

Discovery of novel biaryl benzoxazepinones as dual-mode receptor-interacting protein kinase-1 (RIPK1) inhibitors

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

Synthesis and Characterization of Potent RIPK3 Inhibitors Based on a Tricyclic Scaffold.

Design, Synthesis, and Biological Evaluation of 1-Benzyl-1h-pyrazole Derivatives As Receptor Interacting Protein 1 Kinase Inhibitors.

From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases

Discovery of 4-Amino-1,6-dihydro-7h-pyrrolo[2,3-d]pyridazin-7-one Derivatives As Potential Receptor-Interacting Serine/threonine-Protein Kinase 1 (RIPK1) Inhibitors

Inhibition of RIPK1 by ZJU-37 Promotes Oligodendrocyte Progenitor Proliferation and Remyelination Via NF-κB Pathway

Structure-based Optimizations of a Necroptosis Inhibitor (SZM594) As Novel Protective Agents of Acute Lung Injury

Scaffold Hopping Derived Novel Benzoxazepinone RIPK1 Inhibitors As Anti-Necroptosis Agents.

Discovery of Novel 2,8-Diazaspiro[4.5]decan-1-one Derivatives As Potent RIPK1 Kinase Inhibitors

Discovery and optimization of 3-(indolin-5-yloxy)pyridin-2-amine derivatives as potent necroptosis inhibitors

Targeting Receptor-Interacting Protein Kinase 1 by Novel Benzothiazole Derivatives: Treatment of Acute Lung Injury Through the Necroptosis Pathway

Discovery of 5‐(1‐benzyl‐1H‐imidazol‐4‐yl)‐1,2,4‐oxadiazole derivatives as novel RIPK1 inhibitors via structure‐based virtual screening